Status In progress
Process HST
ID number 861

Project Team

Project lead Joanne Ekeledo

Email enquiries

Consultees

Companies sponsors Aegerion Pharmaceuticals Ltd
Others Department of Health
  NHS England
Patient carer groups Diabetes UK
  Lipodystrophy UK
Professional groups Royal College of Physicians

Commentators

Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Health Improvement Scotland
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
30 August 2019 Appeal
05 August 2019 NICE received an appeal against the Final Evaluation Determination on the above HST evaluation from the following organisations: • Aegerion Pharmaceuticals • Lipodystrophy UK The company which markets this technology (Aegerion Pharmaceuticals) has requested reconsideration of this topic in line with the HST Interim Methods and Process guide, to undertake further work to address the concerns outlined by the committee. Consequently, the Final Evaluation Document for this evaluation is being withdrawn. Therefore an appeal hearing will not be held. A further update will be provided in due course
05 August 2019 Appeal
22 July 2019 NICE received two appeals against the Final Evaluation Determination on the above HST evaluation from the following organisations: • Aegerion Pharmaceuticals • Lipodystrophy UK The appeal panel will convene on Friday 30 August 2019 at NICE, 10 Spring Gardens, London, SW1A 2BU to hear oral representations from the appellants.
12 February 2019 Committee meeting: 2
14 August 2018 The forthcoming committee meeting to discuss metreleptin for treating lipodystrophy on Wednesday 24 October 2018 has been rearranged to enable the company to prepare and submit additional information for committees consideration. Metreleptin for treating lipodystrophy will be now considered by committee on Tuesday 12 February 2019.
23 July 2018 - 13 August 2018 Evaluation consultation: 1
28 June 2018 Committee meeting: 1
08 November 2017 Invitation to participate
21 April 2017 Referral
21 April 2017 In progress, Topic referred
21 November 2016 - 19 December 2016 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance